Compare Halliburton Company (HAL) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Halliburton Company trades at $32.56 (market cap $27.14B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.71 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 2.2× Halliburton Company's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold Halliburton Company for 89 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| HAL | TAK | |
|---|---|---|
Market Cap | $27.14B | $58.74B |
Volume | 11,258,156 | 3,110,994 |
Sector | Energy | Health |
52-Week High | $42.98 | $19.05 |
52-Week Low | $21.82 | $13.23 |
Typical Hold Time | 89 Days | 1 Days |
Enterprise Value | $33.29B | $86.65B |
Dividend Yield | 2.09% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $32.57, up 2.58% today, with a bearish technical signal despite recent earnings beats. The company shows solid profitability with a 7.16% net income margin and 14.89% ROE, though revenue dipped slightly in 2025. Recent news highlights expansion in Venezuela and a new deepwater contract in Cyprus, signaling growth initiatives. Analyst consensus is strongly bullish with a $43.11 price target, but technical indicators and recent CFO stock sales introduce caution.
The outlook for HAL is mixed; strong analyst support and strategic contracts offer upside, but technical weakness and exposure to oil price volatility pose risks. Investors should weigh the company's solid fundamentals and growth projects against market sentiment and industry cyclicality for balanced decision-making.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
